Seres Therapeutics to Cut Staff by 25%, Extend Cash Runway
By Dean Seal
Seres Therapeutics will reduce its workforce by 25% and extend its cash runway into the second quarter of next year as it finalizes the protocol for a study of its bloodstream infections prevention program.
The biotherapeutics company said Tuesday that the job cuts are part of a streamlining of its operations, with a plan to keep the personnel that are key to preparing for a planned Phase 2 study of SER-155.
SER-155 is Seres' lead biotherapeutic program, aimed at preventing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant.
The Food and Drug Administration recently provided feedback on the Phase 2 study protocol for SER-155, which is expected to support finalization of that protocol, Seres said.
The job cuts and other cost saving initiatives should help Seres extend its cash runway into the second quarter of 2026. The workforce reduction is expected to cost Seres about $1 million to $1.4 million in cash, primarily from severance costs, which will be paid out in the fourth quarter of this year.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 23, 2025 07:53 ET (11:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States